ReviewFrontiers in pharmacology2014
Safety of liposome extended-release bupivacaine for postoperative pain control.
Review in Frontiers in pharmacology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Effect of EXPAREL® on Postsurgical Pain, and the Use of Narcotics
A Placebo-controlled, Double-blinded, Randomized Pilot Study of Bupivacaine Liposome Injectable Suspension (EXPAREL) for Minimally Invasive Supracervical Hysterectomies Postsurgical Analgesia
Who cites it
17 citing papers in PubMed, 54 citations in OpenAlex.
- Effects of Liposomal Bupivacaine for Superficial Parasternial Intercostal Plane Block on Postoperative Stress and Analgesia in Patients Undergoing Median Sternotomy: A Prospective, Randomized, Double-Blind Trial.Drug design, development and therapy · 2026Trial
- Trial
- Analgesic effect of single-shot ropivacaine at different layers of the surgical site in primary total hip arthroplasty: a randomised, controlled, observer-blinded study.Journal of orthopaedic surgery and research · 2021Trial
- Effect of Liposomal Bupivacaine for Fascia Iliaca Compartment Block on Early Postoperative Recovery Quality in Elderly Patients Undergoing Total Hip Arthroplasty: A Retrospective Cohort Study.Drug design, development and therapy · 2026Article
- Evolving Trends and Core Contributors: A Bibliometric Update on Liposomal Bupivacaine.Pain research & management · 2026Article
- Local Delivery of Non-opioid Analgesic Microparticles to Modulate Post-surgical Pain.Pharmaceutical research · 2025Article
- Liposomal bupivacaine intercostal nerve block for pain control in thoracoscopic surgery: a randomized controlled trial.Frontiers in medicine · 2025Article
- Bupivacaine Pharmacokinetics and Breast Milk Excretion of Liposomal Bupivacaine Administered After Cesarean Birth.Obstetrics and gynecology · 2020Article
- Can Liposomal Bupivacaine Be Safely Utilized in Elective Spine Surgery?Global spine journal · 2019Article
- Defining local nerve blocks for feline distal pelvic limb surgery: a cadaveric study.Journal of feline medicine and surgery · 2017Article
- Review
- Thoracic epidural catheter for postoperative pain control following an ineffective transversus abdominis plane block using liposome bupivacaine.Journal of pain research · 2017Article
- An extended release local anaesthetic: potential for future use in veterinary surgical patients?Veterinary medicine and science · 2016Review
- Wide Awake Trigger Finger Release Surgery: Prospective Comparison of Lidocaine, Marcaine, and Exparel.Hand (New York, N.Y.) · 2016Article
- Local bupivacaine for postoperative pain management in thyroidectomized patients: A prospective and controlled clinical study.Ulusal cerrahi dergisi · 2016Article
- Unanticipated transient sciatic nerve deficits from intra-wound liposomal bupivacaine injection during total hip arthroplasty.Arthroplasty today · 2015Article
- Postoperative Pain and Length of Stay Lowered by Use of Exparel in Immediate, Implant-Based Breast Reconstruction.Plastic and reconstructive surgery. Global open · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIdeal postoperative pain management requires a multidisciplinary approach in combination with a variety of dosage regimens. Approximately 21-30% of patients experience moderate to severe pain in the postoperative period, which may have a significant impact on recovery rate, standard of living, psychological health, and postoperative complications.
objectiveAnalysis of the incidence and characterization of reported adverse effects with DepoFoam bupivacaine compared to conventional bupivacaine or placebo.
methodsA systematic review of prospective studies on the use of DepoFoam versus bupivacaine or placebo was performed in order to answer the clinically relevant question: is DepoFoam a safer formulation in place of bupivacaine single injection or continuous local infusion techniques for postoperative pain management? Inclusion criteria required randomized, controlled, double-blind trials in patients 18 years old or older, single dose used for postoperative pain control, and a primary procedure performed.
resultsSix studies fitted the inclusion criteria for analysis, DepoFoam bupivacaine used in therapeutic doses was well-tolerated, had a higher safety margin, and showed a favorable safety profile compared to bupivacaine and control groups.
conclusionExtended drug delivery system DepoFoam bupivacaine is a promising drug formulation that may significantly improve postoperative care and pain control in surgical patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.